In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses.

ABSTRACT:

Background

Rhinovirus infections do not only cause common colds, but may also trigger severe exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Even though rhinoviruses have been the focus of extensive drug development efforts in the past, an anti-rhinoviral drug still has to make it to the market. In the past, the viral capsid protein VP1 has been shown to be an important target for the development of antiviral molecules. Furthermore, many different chemical scaffolds appear to possess the properties that are required to inhibit virus replication by this mechanism of action. I-6602, an analogue of the rhinovirus inhibitor pirodavir, was previously identified as a potent inhibitor of rhinovirus infection. Here, we describe the antiviral activity of its analog

SUBMITTER: Lacroix C 

PROVIDER: S-EPMC4501209 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature